PMS29 - SECUKINUMAB VERSUS ADALIMUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AMONG 52 WEEKS FROM A TUNISIAN PERSPECTIVE.

Abstract

The objective of this analysis was to assess and compare the long term cost per responder (CPR) based on the Assessment of SpondyloArthritis International Society (ASAS) outcomes following 52 weeks of treatment with Secukinumab (SEC,150mg) relative to Adalimumab (ADA, anti TNF) for the treatment of Ankylosing Spondylitis (AS) in Tunisia. The CPR for each treatment namely Secukinumab and Adalimumab was estimated by dividing the acquisition cost of each drug by its response rate. Drug costs were estimated based on the Tunisian Central Pharmacy (PCT) database (currency in TND) and the number of doses required during 52 weeks. The long-term response rates were derived from a matching-adjusted indirect comparison (MAIC) technique based on the data from MEASURE 2 and ATLAS clinical trials of Secukinumab and Adalimumab respectively. MAIC analysis matched patient populations on key baseline parameters. MAIC analysis showed that ASAS (20, 40 and 5/6) response rates were significantly higher for SEC 150 mg compared to ADA at 52 weeks. ASAS 20 response rates were 81% and 65%, ASAS 40 response rates were 62% and 47% whereas the ASAS 5/6 response rates were 74%, and 55% for SEC150 mg and ADA respectively. SEC has a lower CPR compared to ADA among AS patients. Cost per ASAS 20 responder were TND 29,171.00 and TND 56,534.00 cost per ASAS40 responder were TND 37,922.00 and TND 78,603.00 whereas costs per ASAS 5/6 responder were TND 31,772.00 and TND 67,255.00 for SEC 150 mg and ADA respectively. These findings support the economic advantage of SEC over ADA. With SEC, Tunisian AS patient could be treated more efficiently compared to ADA.